About Us

Vision & Mission

About Duchenne

Research

Financials

The Boys

 
Prosensa Moves Forward!

Prosensa is staying true to their business plan, and CureDuchenne is pleased to have been an early and strong supporter of this company.

Read their press release, issued today (April 17, 2007):

SynCo Bio Partners B.V. Signs Pharmaceutical Service Agreement With Prosensa B.V. for RNA Based Therapeutics for the Treatment of Duchenne Muscular Dystrophy

 Read about our initial support of Prosensa:  

10-May-06	CureDuchenne & Prosensa's Partnership Moves Forward …Results in Major Step Forward to Develop an Effective Therapy for Duchenne Muscular Dystrophy
06-Dec-05	FDA Grants Prosensa Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy Using Exon Skipping
14-Dec-04	CureDuchenne to Fund Prosensa Development of Potential Duchenne Muscular Dystrophy Therapy for Pre-clinical & Clinical Trials

Powered by CityMax.com